GleamWall
中文EN

NRSN NeuroSense Therapeutics Ltd. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1875091 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-9.0%
TTM EPS YoY18.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-2,175.0%
ROA-397.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets251.8%
Debt / equity—
Current ratio0.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.69x
Accruals ratio-123.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY2021*2021-12-31
Income statement
Revenue—————
R&D expense$6.23M$5.70M$7.27M$5.59M—
SG&A expense$4.86M$4.20M$4.78M$4.97M$2.50M
Operating income-$11.09M-$9.90M-$12.05M-$10.55M-$5.59M
Interest expense——$2.21M$45,000$1.19M
Net income-$11.12M-$10.21M-$10.11M-$10.49M-$4.04M
EBITDA-$11.07M-$9.88M-$12.03M-$10.54M—
EPS (basic)-0.44-0.54-0.74-0.91-0.65
EPS (diluted)-0.44-0.54-0.74-0.91-0.65
Weighted avg. shares (diluted)25.48M18.60M13.64M11.50M—
Balance sheet
Cash & equivalents$166,000$3.38M$2.64M$3.54M$11.06M
Short-term investments———$3.55M—
Current assets$778,000$4.40M$2.92M$7.38M$11.41M
PP&E, net$58,000$66,000$85,000$77,000$19,000
Total assets$1.03M$4.58M$3.19M$7.72M$11.43M
Current liabilities$2.52M$1.99M$3.46M$1.73M$597,000
Total liabilities$2.59M$1.99M$4.94M$1.87M$2.42M
Shareholders' equity-$1.56M$2.58M-$1.76M$5.84M$10.83M
Shares outstanding32.56M23.23M15.38M11.78M2.00M
Cash flow statement
Operating cash flow-$7.67M-$10.13M-$8.35M-$7.62M-$1.54M
Capital expenditure$8,000$3,000$29,000$70,000$17,000
Free cash flow-$7.68M-$10.14M-$8.38M-$7.69M-$1.56M
Investing cash flow-$8,000$1,000$3.47M-$3.59M-$17,000
Financing cash flow$4.43M$10.91M$3.98M$3.77M$11.90M
Depreciation & amortization$16,000$22,000$21,000$12,000—
Stock-based compensation$2.14M$557,000$1.54M$1.73M$4.16M
Dividends paid——$310,000$310,000$29,000

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.